Instructions for Using the eBPDR System

For use by biological product manufacturers to report biological product deviations (BPD) that may affect the safety, purity, or potency of a distributed product in accordance with 21 CFR, Part 600.14 or 606.171. Also for use by Human Cells, Tissues and Cellular and Tissue-Based Product (HCT/P) manu

Read the full story at FDA what's new: biologics (opens in a new tab)

Headline and summary from FDA what's new: biologics; the full story is on the publisher's site. Nothing here is investment advice.